DRE Treatment for Adults - VNS Therapy Epilepsy

Studies have shown that VNS Therapy^™ is an effective treatment option

No “honeymoon effect” with VNS Therapy²

Change from baseline in total number of seizures per week was significantly greater with VNS Therapy + BMP vs BMP only (p=0.03)

Change from baseline in total number of seizures per week was significantly greater with VNS Therapy + Best Medical Practice (BMP) vs Best Medical Practice (BMP) only (p=0.03)

Seizure reduction that continues to improve over time³

Seizure frequency significantly reduced from baseline at each recorded interval over 10 years (p<0.001) in patients with partial and generalized seizures

VNS Therapy significantly reduces Depressive Symptoms in Patients with Drug-Resistant Epilepsy

VNS Therapy is associated with a reduction in depressive symptoms measured on Beck Depression Inventory (BDI) and Montgomery-Asberg Depression Rating Scale (MADRS)⁶

Accidents and injuries reduced post-VNS Therapy

The incidence of hospitalisations, A&E visits, fractures and head trauma were significantly reduced post-VNS Therapy compared to pre-VNS Therapy periods⁷

Improved alertness, mood and memory in DRE patients treated with VNS Therapy⁸

VNS Therapy™ has proven safety and tolerability profile with side effects reducing over time^13,14

Safety Profile

VNS Therapy^™ has no drug interactions and does not cause drug-related toxic central nervous system side effects.¹⁵

The most common adverse events following stimulation (>5%) were voice alterations, increased coughing, pharyngitis, paresthesia, dyspnea, dyspepsia, and nausea. These side effects typically occur only during stimulation and generally become less noticeable over time for most patients^12,13,15

Infection is the most common complication of the surgical procedure. Children (<12 years of age) may have a greater risk for infection when compared to adolescent and adult patients (≥12 years).¹²

For more safety information click here.

References

1. VNS Therapy™ System Epilepsy Physician’s Manual April 2021, 76-0000-5600/8 (OUS) 2. Ryvlin P, et al. Epilepsia. 2014;55:893–900. 3. Elliott RE, et al. Epilepsy Behav. 2011;20:478–83. 4. Elliott RE, et al. Epilepsy Behav 2011;20(1):57‐63. Kawai K, et al. Epileptic Disord 2017;19(3):1‐12. Heck et al 2014 Neurology. Skarpaas et al 2017. Salnova et al 2015 Neurology (SANTE). VNS Therapy™ System Epilepsy Physician’s Manual April 2021, 76-0000-5600/8 (OUS) 5. Hamilton P, et al. Seizure. 2018;58:120–6. DeGiorgio CM, et al. Epilepsia. 2000;41:1195–200. 6. Spindler et al, 2019. Seizure, 69:77-79 7. Helmers et al, 2011. Jrnl of European Paediatric Neurology Society, 16:449-458 8. Sun et al, 2017. Journal of Clinical and Experimental Neuropsychology. 1-11 9. Helmers et al Eur J Paediatr Neurol. 2012 Sep; 16(5):449-58

VNS Therapy™ treatment in adult patients

Studies have shown that VNS Therapy^™ is an effective treatment option

VNS Therapy requires a less invasive implantation procedure than other implantable devices for DRE⁴

Beyond seizures, VNS Therapy™ may reduce the impact of comorbidities in patients with drug-resistant epilepsy

In DRE, comorbidities are significant contributors to a reduced quality of life

VNS Therapy is associated with a reduction in depressive symptoms measured on Beck Depression Inventory (BDI) and Montgomery-Asberg Depression Rating Scale (MADRS)⁶

The incidence of hospitalisations, A&E visits, fractures and head trauma were significantly reduced post-VNS Therapy compared to pre-VNS Therapy periods⁷

Improved alertness, mood and memory in DRE patients treated with VNS Therapy⁸

VNS Therapy™ has been shown to be associated with a reduction of hospitalisations and health related events⁹

Consider the comorbidities when treating DRE and how VNS Therapy could help to reduce the consequences of drug-resistant epilepsy for your patients.

VNS Therapy™ has proven safety and tolerability profile with side effects reducing over time^13,14

Safety Profile

Email Alerts

Choose a country

To see the other countries, please click here.

VNS Therapy™ treatment in adult patients

Studies have shown that VNS Therapy™ is an effective treatment option

VNS Therapy requires a less invasive implantation procedure than other implantable devices for DRE4

Beyond seizures, VNS Therapy™ may reduce the impact of comorbidities in patients with drug-resistant epilepsy

In DRE, comorbidities are significant contributors to a reduced quality of life

VNS Therapy is associated with a reduction in depressive symptoms measured on Beck Depression Inventory (BDI) and Montgomery-Asberg Depression Rating Scale (MADRS)6

The incidence of hospitalisations, A&E visits, fractures and head trauma were significantly reduced post-VNS Therapy compared to pre-VNS Therapy periods7

Improved alertness, mood and memory in DRE patients treated with VNS Therapy8

VNS Therapy™ has been shown to be associated with a reduction of hospitalisations and health related events9

Consider the comorbidities when treating DRE and how VNS Therapy could help to reduce the consequences of drug-resistant epilepsy for your patients.

VNS Therapy™ has proven safety and tolerability profile with side effects reducing over time13,14

Safety Profile

Email Alerts

Choose a country

To see the other countries, please click here.

Studies have shown that VNS Therapy^™ is an effective treatment option

VNS Therapy requires a less invasive implantation procedure than other implantable devices for DRE⁴

VNS Therapy is associated with a reduction in depressive symptoms measured on Beck Depression Inventory (BDI) and Montgomery-Asberg Depression Rating Scale (MADRS)⁶

The incidence of hospitalisations, A&E visits, fractures and head trauma were significantly reduced post-VNS Therapy compared to pre-VNS Therapy periods⁷

Improved alertness, mood and memory in DRE patients treated with VNS Therapy⁸

VNS Therapy™ has been shown to be associated with a reduction of hospitalisations and health related events⁹

VNS Therapy™ has proven safety and tolerability profile with side effects reducing over time^13,14